Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Park, Eu Jeen Yang, Young Tak Lim, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Meerim Park, Hyeon Jin Park, Byung-Kiu Park, Jun Ah Lee, Jun Eun Park, Soon Ki Kim, Ji Yoon Kim, Hyo Sun Kim, Youngeun Ma, Kyung Duk Park, Sang Kyu Park, Eun Sil Park, Ye Jee Shim, Eun Sun Yoo, Kyung Ha Ryu, Jae Won Yoo, Yeon Jung Lim, Hoi Soo Yoon, Mee Jeong Lee, Jae Min Lee, In-Sang Jeon, Hye Lim Jung, Hee Won Chueh, Seunghyun Won, the Korean Pediatric Hematology and Oncology Group (KPHOG)
Cancer Res Treat. 2023;55(1):279-290. Published online August 11, 2022
Purpose
Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea.
Materials and Methods
From January 2001 to December 2015, data of pediatric patients (0–18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.
Results
Among 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range 0-225.5) and median follow-up duration was 88.5 months (range 0-211.6). Overall, 32 patients died, of whom 17, 11, 1, and 3 died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).
Conclusion
The pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea.
Citations
Citations to this article as recorded by
Congenital Mesoblastic Nephroma Mimic Wilms Tumor on 18F-FDG PET/CT and PET/MR Wenzhu Hu, Chunxia Qin, Fuqiang Shao, Mengting Li, Xiaoli Lan Clinical Nuclear Medicine.2024; 49(4): 353. CrossRef
Progress towards Therapies for Solid Renal Tumors in Children 洁 林 Advances in Clinical Medicine.2024; 14(06): 245. CrossRef
Md. Enamul Haque, Fatima Khan, Lianhua Chi, Smriti Gurung, Sri Murugan Poongkavithai Vadevoo, Rang-Woon Park, Dong-Kyu Kim, Sang Kyoon Kim, Byungheon Lee
Cancer Res Treat. 2019;51(3):861-875. Published online October 1, 2018
Purpose
This study was carried out to identify a peptide that selectively binds to kidney injury molecule-1 (KIM-1) by screening a phage-displayed peptide library and to use the peptide for the detection of KIM-1overexpressing tumors in vivo.
Materials and Methods
Biopanning of a phage-displayed peptide library was performed on KIM-1–coated plates. The binding of phage clones, peptides, and a peptide multimer to the KIM-1 protein and KIM-1–overexpressing and KIM-1–low expressing cells was examined by enzyme-linked immunosorbent assay, fluorometry, and flow cytometry. A biotin-peptide multimer was generated using NeutrAvidin. In vivo homing of the peptide to KIM-1–overexpressing and KIM1–low expressing tumors in mice was examined by whole-body fluorescence imaging.
Results
A phage clone displaying the CNWMINKEC peptide showed higher binding affinity to KIM-1 and KIM-1–overexpressing 769-P renal tumor cells compared to other phage clones selected after biopanning. The CNWMINKEC peptide and a NeutrAvidin/biotin-CNWMINKEC multimer selectively bound to KIM-1 over albumin and to KIM-1–overexpressing 769-P cells and A549 lung tumor cells compared to KIM-1-low expressing HEK293 normal cells. Co-localization and competition assays using an anti–KIM-1 antibody demonstrated that the binding of the CNWMINKEC peptide to 769-P cells was specifically mediated by KIM-1. The CNWMINKEC peptide was not cytotoxic to cells and was stable for up to 24 hours in the presence of serum. Whole-body fluorescence imaging demonstrated selective homing of the CNWM-INKEC peptide to KIM-1–overexpressing A498 renal tumor compared to KIM1–low expressing HepG2 liver tumor in mice.
Conclusion
The CNWMINKEC peptide is a promising probe for in vivo imaging and detection of KIM-1‒overexpressing tumors.
Citations
Citations to this article as recorded by
Bi-functional KIT-PR1P peptides combine with VEGF to protect ischemic kidney in rats by targeting to Kim-1 Runxue Zhou, Hang Liu, Xianglin Hou, Qi Liu, Shuwei Sun, Xiaoge Li, Wenxuan Cao, Weihong Nie, Chunying Shi, Wei Chen Regenerative Therapy.2024; 25: 162. CrossRef
Improving Pharmacokinetics of Peptides Using Phage Display Mallika Asar, Jessica Newton-Northup, Mette Soendergaard Viruses.2024; 16(4): 570. CrossRef
Unveiling Invisible Extracellular Vesicles: Cutting‐Edge Technologies for Their in Vivo Visualization Prakash Gangadaran, Fatima Khan, Ramya Lakshmi Rajendran, Akanksha Onkar, Anshika Goenka, Byeong‐Cheol Ahn WIREs Nanomedicine and Nanobiotechnology.2024;[Epub] CrossRef
Tumor microenvironment signaling and therapeutics in cancer progression Anshika Goenka, Fatima Khan, Bhupender Verma, Priyanka Sinha, Crismita C. Dmello, Manasi P. Jogalekar, Prakash Gangadaran, Byeong‐Cheol Ahn Cancer Communications.2023; 43(5): 525. CrossRef
Specific bFGF targeting of KIM-1 in ischemic kidneys protects against renal ischemia-reperfusion injury in rats Siqi Song, Xianglin Hou, Weiwei Zhang, Xinyu Liu, Wei Wang, Xiaoya Wang, Wenxuan Cao, Yujun Xia, Wei Chen, Chunying Shi Regenerative Biomaterials.2022;[Epub] CrossRef
Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy Chunyan Li, Jia Li, Ying Xu, Ying Zhan, Yu Li, Tingting Song, Jiao Zheng, Hong Yang International Journal of Peptide Research and Therapeutics.2021; 27(1): 587. CrossRef
Detection of kidney disease biomarkers based on fluorescence technology Bicheng Yao, Marie-Claire Giel, Yuning Hong Materials Chemistry Frontiers.2021; 5(5): 2124. CrossRef
Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library Shuhui Zhao, Chunyan Li, Yunge Gao, Luomeng Qian, Jian Dong, Lianghao Zhai, Biliang Chen, Jianfang Zhang International Journal of Peptide Research and Therapeutics.2021; 27(3): 1741. CrossRef
Purpose
The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population.
Materials and Methods
Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9.
Results
There was no significant difference between the groups in terms of any of the functioning sub-scales and symptoms, except significantly lower social functioning observed in BC survivors than that observed in KC survivors. Although the three groups of UC survivors showed essentially similar functioning sub-scales and symptoms when compared to the general population, PC and BC survivors showed significantly lower social functioning and a lower appetite than that observed in controls. KC survivors showed lower physical functioning, as well as higher pain and dyspnea. Although all three groups of UC survivors reported higher financial difficulties, they also reported higher perceived social support than that reported by the non-cancer control group. No statistically significant difference was observed in terms of depressive symptoms between each group of UC survivors and the general population.
Conclusion
Disease-free survivors of the three major types of UCs showed generally similar HRQoL compared to the general population, as well as compared to each other.
Citations
Citations to this article as recorded by
Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder So Hee Kim, Eunjung Ryu, Byong Chang Jeong Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100490. CrossRef
The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score‐matched study Giuseppe Palermo, Francesco Pio Bizzarri, Eros Scarciglia, Emilio Sacco, Koosha Moosavi Seyed, Pierluigi Russo, Filippo Gavi, Battista Filomena Giovanni, Francesco Rossi, Marco Campetella, Angelo Totaro, Nazario Foschi, Marco Racioppi International Journal of Urology.2024; 31(12): 1423. CrossRef
Factors Affecting the Health-Related Quality of Life of Patients with Bladder Cancer Haetsal Kwon, Hyojung Park Journal of Korean Public Health Nursing.2024; 38(3): 358. CrossRef
Properties of the Shift and Persist Questionnaire in adolescent and young adult cancer patients and survivors: Validity, consistency, and interpretability Karly M. Murphy, Edith Chen, Edward H. Ip, Abby R. Rosenberg, Mallory A. Snyder, John M. Salsman Quality of Life Research.2023; 32(1): 273. CrossRef
Adoption of patient communication rules in clinical practice and the role of faith-based communities in shaping them: the palliative aspect of spiritual support Konstantin Sokolovskiy, Olga Pashanova, Vladimir Beketov, Andrey Aleshkin Mental Health, Religion & Culture.2023; 26(1): 16. CrossRef
Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson Journal of Cancer Survivorship.2022; 16(6): 1279. CrossRef
Mental Health in Urologic Oncology Danyon Anderson, Abrahim N. Razzak, Matthew McDonald, David Cao, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits Health Psychology Research.2022;[Epub] CrossRef
Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review Liliana Vartolomei, Manuela Schmidinger, Mihai Vartolomei, Shahrokh Shariat Journal of Clinical Medicine.2022; 11(21): 6383. CrossRef
Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status Kisook Kim, Hyohyeon Yoon International Journal of Environmental Research and Public Health.2021; 18(7): 3803. CrossRef
Feasibility of a socio-spiritual intervention to improve quality of life of adult Nigerians with cancer and their family caregivers: Protocol for a randomised controlled trial Israel Gabriel, Debra Creedy, Elisabeth Coyne Contemporary Clinical Trials Communications.2021; 22: 100802. CrossRef
Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker Supportive Care in Cancer.2020; 28(6): 2875. CrossRef
Comorbid depression in medical diseases Stefan M. Gold, Ole Köhler-Forsberg, Rona Moss-Morris, Anja Mehnert, J. Jaime Miranda, Monika Bullinger, Andrew Steptoe, Mary A. Whooley, Christian Otte Nature Reviews Disease Primers.2020;[Epub] CrossRef
Health-related Quality of Life and Its Related Factors among Cancer Survivors and General Adults: Focusing on Lifestyle Behaviors and Mental Health Eun A Song, Youngran Kweon, Yoon Young Hwang, Minjeong An Korean Journal of Adult Nursing.2020; 32(4): 385. CrossRef
Age and gender differences in anxiety and depression in cancer patients compared with the general population Andreas Hinz, Philipp Yorck Herzberg, Florian Lordick, Joachim Weis, Hermann Faller, Elmar Brähler, Martin Härter, Karl Wegscheider, Kristina Geue, Anja Mehnert European Journal of Cancer Care.2019;[Epub] CrossRef
Purpose
The purpose of this study was to determine the impact of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), statin, and cyclooxygenase 2 (COX-2) inhibitor on the development of kidney, prostate, and urothelial cancers by analyzing the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) database.
Materials and Methods
Among a representative sample cohort of 1,025,340 participants in NHIS-NSC database in 2002, we extracted data of 799,850 individuals who visited the hospital more than once, and finally included 321,122 individuals aged 40 and older. Following a 1-year washout period between 2002 and 2003, we analyzed 143,870 (male), 320,861 and 320,613 individuals for evaluating the risk of prostate cancer, kidney cancer and urothelial cancer developments, respectively, during 10-year follow-up periods between 2004 and 2013. The medication group consisted of patients prescribed these drugs more than 60% of the time in 2003. To adjustfor various parameters of the patients, a multivariate Cox regression model was adopted.
Results
During 10-year follow-up periods between 2004 and 2013, 9,627 (6.7%), 1,107 (0.4%), and 2,121 (0.7%) patients were diagnosed with prostate cancer, kidney cancer, and urothelial cancer, respectively. Notably, multivariate analyses revealed that NSAIDs significantly increased the risk of prostate cancer (hazard ratio [HR], 1.35). Also, it was found that aspirin (HR, 1.28) and statin (HR, 1.55) elevated the risk of kidney cancer. No drugs were associated with the risk of urothelial cancer.
Conclusion
In sum, our study provides the valuable information for the impact of aspirin, NSAID, statin, and COX-2 inhibitor on the risk of prostate, kidney, and urothelial cancer development and its survival outcomes.
Citations
Citations to this article as recorded by
Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis Tzu Shuang Chen, Hui Ying Liu, Yin Lun Chang, Yao Chi Chuang, Yen Ta Chen, Yu Li Su, Chun Chieh Huang, Yen Ting Wu, Hung Jen Wang, Hao Lun Luo The World Journal of Men's Health.2024; 42(3): 630. CrossRef
Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun The World Journal of Men's Health.2023; 41(1): 110. CrossRef
Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes Irmina Maria Michalek, Rebecca E. Graff, Alejandro Sanchez, Toni K. Choueiri, Eunyoung Cho, Mark A. Preston, Kathryn M. Wilson Acta Oncologica.2023; 62(9): 988. CrossRef
Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies Shaodi Ma, Weihang Xia, Birong Wu, Chenyu Sun, Yuemeng Jiang, Haixia Liu, Scott Lowe, Zhen Zhou, Peng Xie, Juan Gao, Linya Feng, Xianwei Guo, Guangbo Qu, Yehuan Sun European Journal of Clinical Pharmacology.2023; 79(11): 1475. CrossRef
Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review Hwanik Kim, Jung Kwon Kim The World Journal of Men's Health.2022; 40(3): 412. CrossRef
The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study Fei Chen, Peggy Wan, Lynne R. Wilkens, Loïc Le Marchand, Christopher A. Haiman Cancer Epidemiology, Biomarkers & Prevention.2022; 31(5): 999. CrossRef
Aspirin and the risk of nondigestive tract cancers: An updated meta‐analysis to 2019 Claudia Santucci, Silvano Gallus, Marco Martinetti, Carlo La Vecchia, Cristina Bosetti International Journal of Cancer.2021; 148(6): 1372. CrossRef
Association between depression and risk of Parkinson's disease in South Korean adults Wonjeong Jeong, Hyunkyu Kim, Jae Hong Joo, Sung-In Jang, Eun-Cheol Park Journal of Affective Disorders.2021; 292: 75. CrossRef
Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment Bo Fan, Alradhi Mohammed, Yuanbin Huang, Hong Luo, Hongxian Zhang, Shenghua Tao, Weijiao Xu, Qian Liu, Tao He, Huidan Jin, Mengfan Sun, Man Sun, Zhifei Yun, Rui Zhao, Guoyu Wu, Xiancheng Li Frontiers in Oncology.2021;[Epub] CrossRef
Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study Luyang Liu, Chao Sheng, Zhangyan Lyu, Hongji Dai, Kexin Chen Frontiers in Nutrition.2021;[Epub] CrossRef
Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study Charlotte Skriver, Christian Dehlendorff, Michael Borre, Klaus Brasso, Signe Benzon Larsen, Anne Tjønneland, Anton Pottegård, Jesper Hallas, Henrik Toft Sørensen, Søren Friis Cancer Causes & Control.2020; 31(2): 139. CrossRef
Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors Shipra Gandhi, Manu Pandey, Nischala Ammannagari, Chong Wang, Mark J Bucsek, Lamya Hamad, Elizabeth Repasky, Marc S Ernstoff Immunotherapy.2020; 12(2): 141. CrossRef
Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis Michael M Ward, Sara Alehashemi Rheumatology.2020; 59(12): 3817. CrossRef
Complex roles of the old drug aspirin in cancer chemoprevention and therapy Hui Hua, Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang Medicinal Research Reviews.2019; 39(1): 114. CrossRef
Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform Chang Wook Jeong, Jungyo Suh, Hyeong Dong Yuk, Bum Sik Tae, Miso Kim, Bhumsuk Keam, Jin Ho Kim, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim, Kyung Chul Moon, Gi Jeong Cheon, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak Investigative and Clinical Urology.2019; 60(4): 235. CrossRef
The impact of acute inflammation on progression and metastasis in pancreatic cancer animal model Keun Soo Ahn, Ji Yeon Hwang, Ho-Seong Han, Sang Tae Kim, Ilseon Hwang, Young-Ok Chun Surgical Oncology.2018; 27(1): 61. CrossRef
Prostate cancer multifocality, the index lesion, and the microenvironment Rafael R. Tourinho-Barbosa, Jean de la Rosette, Rafael Sanchez-Salas Current Opinion in Urology.2018; 28(6): 499. CrossRef
Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis Zhenhua Shang, Xue Wang, Hao Yan, Bo Cui, Qi Wang, Jiangtao Wu, Xin Cui, Jin Li, Tongwen Ou, Kun Yang Frontiers in Oncology.2018;[Epub] CrossRef
Purpose Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.
Citations
Citations to this article as recorded by
Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang European Journal of Pediatrics.2023; 183(2): 557. CrossRef
Infantile Extracranial Rhabdoid Tumor of the Scalp Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as Case Reports in Medicine.2021; 2021: 1. CrossRef
Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin Bone Marrow Transplantation.2020; 55(1): 137. CrossRef
Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto Pediatric Blood & Cancer.2016; 63(2): 352. CrossRef